The chemokine system and CCR5 antagonists: Potential in HIV treatment and other novel therapies

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 2, 2009, Pages 147-160

  Dhami, H ^a   Fritz, C E ^a   Gankin, B ^a   Pak, S H ^a   Yi, W ^a   Seya, M J ^a   Raffa, R B ^a   Nagar, S ^a,b  

^a TEMPLE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Chemokine receptor 5; Chemokine receptor 5 antagonists; Chemokine receptors; Chemokines; Entry inhibitors; Fusion inhibitors; Human immunodeficiency virus acquired immune deficiency syndrome; Maraviroc; Vicriviroc

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; APLAVIROC; ATAZANAVIR; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE;

ABDOMINAL PAIN; BLOATING; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DYSLIPIDEMIA; FAT REDISTRIBUTION SYNDROME; FATIGUE; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INJECTION SITE CYST; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; MUSCULOSKELETAL DISEASE; MYOPATHY; NAUSEA; PHARYNGITIS; RASH; REVIEW; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS;

ANIMALS; ANTI-HIV AGENTS; CHEMOKINES; CLINICAL TRIALS AS TOPIC; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE;

EID: 61349189684     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00978.x     Document Type: Review

References (65)

1. Jaffe HW, Bregman DJ, Selik RM (1983) Acquired immune deficiency syndrome in the United States: the first 1,000 cases. Journal of Infectious Diseases, 148, 339 345.
2. Kanki PJ, Hopper JR, Essex M (1987) The origins of HIV-1 and HTLV-4/HIV-2. Annals of the New York Academy of Sciences, 511, 370 375.
3. Gottlieb GS, Hawes SE, Agne HD, Stern JE, Critchlow CW, Kiviat NB, Sow PS (2006) Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. Aids, 20, 895 900.
4. UNAIDS and WHO (2007) AIDS epidemic update. URL: http://data.unaids.org/ pub/EPISlides/2007/2007-epiupdate-en.pdf (accessed 7 July 2008).
5. Sepkowitz KA (2001) AIDS - the first 20 years. New England Journal of Medicine, 344, 1764 1772.
6. Wei X, Ghosh SK, Taylor ME et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 373, 117 122.
7. Maenza J, Flexner C (1998) Combination antiretroviral therapy for HIV infection. American Family Physician, 57, 2789 2798.
8. DHHS (2007) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. URL: http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf (accessed 7 July 2008).
9. Agrawal L, Lu X, Jin Q, Alkhatib G (2006) Anti-HIV therapy: current and future directions. Current Pharmaceutical Design, 12, 2031 2055.
10. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT (2005) Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Current Pharmaceutical Design, 11, 1805 1843.
11. Schinazi RF, Hernandez-Santiago BI, Hurwitz SJ (2006) Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Research, 71, 322 334.
12. Pettit SC, Clemente JC, Jeung JA, Dunn BM, Kaplan AH (2005) Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. Journal of Virology, 79, 10601 10607.
13. Justesen US (2006) Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy. Basic and Clinical Pharmacology and Toxicology, 98, 20 31.
14. FDA US (2007) FDA approves new HIV drug. Raltegravir tablets used in combination with other antiretroviral agents. Available at: http://www.fda.gov/ bbs/topics/NEWS/2007/NEW01726.html (accessed 7 July 2008).
15. Jain R, Clark NM, Diaz-Linares M, Grim SA (2006) Limitations of current antiretroviral agents and opportunities for development. Current Pharmaceutical Design, 12, 1065 1074.
16. Walmsley S (2007) Protease inhibitor-based regimens for HIV therapy: safety and efficacy. Journal of Acquired Immune Deficiency Syndrome, 45 (Suppl 1 S5 S13 quiz S28-S31.
17. Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annual Reviews in Immunology, 25, 787 820.
18. Fernandez EJ, Lolis E (2002) Structure, function, and inhibition of chemokines. Annual Reviews in Pharmacology and Toxicology, 42, 469 499.
19. Oppermann M (2004) Chemokine receptor CCR5: insights into structure, function, and regulation. Cellular Signalling, 16, 1201 1210.
20. Lederman MM, Penn-Nicholson A, Cho M, Mosier D (2006) Biology of CCR5 and its role in HIV infection and treatment. Journal of the American Medical Association, 296, 815 826.
21. Lalani AS, Masters J, Zeng W et al. (1999) Use of chemokine receptors by poxviruses. Science, 286, 1968 1971.
22. Shaheen F, Collman RG (2004) Co-receptor antagonists as HIV-1 entry inhibitors. Current Opinion in Infectious Diseases, 17, 7 16.
23. Belnoue E, Kayibanda M, Deschemin JC, Viguier M, Mack M, Kuziel WA, Renia L (2003) CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood, 101, 4253 4259.
24. Ank N, Petersen K, Malmgaard L, Mogensen SC, Paludan SR (2005) Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2. Journal of Virology, 79, 9831 9841.
25. Machado FS, Koyama NS, Carregaro V et al. (2005) CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. Journal of Infectious Diseases, 191, 627 636.
26. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual Reviews in Immunology, 17, 657 700.
27. Briz V, Poveda E, Soriano V (2006) HIV entry inhibitors: mechanisms of action and resistance pathways. Journal of Antimicrobial Chemotherapy, 57, 619 627.
28. Braun P, Wiesmann F (2007) Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals. European Journal of Medical Research, 12, 463 472.
29. Crabb C (2006) GlaxoSmithKline ends aplaviroc trials. AIDS, 20, 641.
30. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA (2005) Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metabolism and Disposition, 33, 587 595.
31. Este JA, Telenti A (2007) HIV entry inhibitors. Lancet, 370, 81 88.
32. Dorr P, Westby M, Dobbs S et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrobial Agents and Chemotherapy, 49, 4721 4732.
33. Westby M, Smith-Burchnell C, Mori J et al. (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. Journal of Virology, 81, 2359 2371.
34. Rosario MC, Poland B, Sullivan J, Westby M, van der Ryst E (2006) A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. Journal of Acquired Immune Deficiency Syndrome, 42, 183 191.
35. Fatkenheuer G, Pozniak AL, Johnson MA et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Medicine, 11, 1170 1172.
36. Carter NJ, Keating GM (2007) Maraviroc. Drugs, 67, 2277 2288 discussion 2289-2290.
37. Tagat JR, McCombie SW, Nazareno D et al. (2004) Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5- pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S) -methyl-1-piperaz inyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. Journal of Medicinal Chemistry, 47, 2405 2408.
38. Strizki JM, Tremblay C, Xu S et al. (2005) Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy, 49, 4911 4919.
39. Ghosal A, Ramanathan R, Yuan Y, Hapangama N, Chowdhury SK, Kishnani NS, Alton KB (2007) Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metabolism and Disposition, 35, 2186 2195.
40. Schurmann D, Fatkenheuer G, Reynes J et al. (2007) Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS, 21, 1293 1299.
41. Gulick RM, Su Z, Flexner C et al. (2007) Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. Journal of Infectious Diseases, 196, 304 312.
42. Liu YP, Haasnoot J, Berkhout B (2007) Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Research, 35, 5683 5693.
43. Qin XF, An DS, Chen IS, Baltimore D (2003) Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proceedings of the National Academy of Sciences of the United States of America, 100, 183 188.
44. An DS, Donahue RE, Kamata M et al. (2007) Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proceedings of the National Academy of Sciences of the United States of America, 104, 13110 13115.
45. Papworth M, Kolasinska P, Minczuk M (2006) Designer zinc-finger proteins and their applications. Gene, 366, 27 38.
46. Mani M, Kandavelou K, Dy FJ, Durai S, Chandrasegaran S (2005) Design, engineering, and characterization of zinc finger nucleases. Biochemical and Biophysical Research Communications, 335, 447 457.
47. Scott WG (2007) Ribozymes. Current Opinion in Structural Biology, 17, 280 286.
48. Qureshi A, Zheng R, Parlett T et al. (2006) Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA. Biochemical Journal, 394, 511 518.
49. Li M, Li H, Rossi JJ (2006) RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Annals of the New York Academy of Sciences, 1082, 172 179.
50. Swan CH, Torbett BE (2006) Can gene delivery close the door to HIV-1 entry after escape? Journal of Medical Primatology, 35, 236 247.
51. Kontermann RE (2004) Intrabodies as therapeutic agents. Methods, 34, 163 170.
52. Yang AG, Bai X, Huang XF, Yao C, Chen S (1997) Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 94, 11567 11572.
53. Safarian D, Carnec X, Tsamis F, Kajumo F, Dragic T (2006) An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology, 352, 477 484.
54. Yoshimura K, Shibata J, Kimura T et al. (2006) Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS, 20, 2065 2073.
55. Vierboom MP, Zavodny PJ, Chou CC et al. (2005) Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis and Rheumatism, 52, 627 636.
56. Yang YF, Mukai T, Gao P et al. (2002) A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. European Journal of Immunology, 32, 2124 2132.
57. Vaday GG, Peehl DM, Kadam PA, Lawrence DM (2006) Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate, 66, 124 134.
58. Prest SJ, Rees RC, Murdoch C et al. (1999) Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials. Clinical and Experimental Metastasis, 17, 389 396.
59. Donnelly LE, Barnes PJ (2006) Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends in Pharmacological Sciences, 27, 546 553.
60. Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K (2005) Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. European Respiratory Journal, 25, 640 646.
61. Hancock WW, Wang L, Ye Q, Han R, Lee I (2003) Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Current Opinion in Immunology, 15, 479 486.
62. Gong X, Feng H, Zhang S, Yu Y, Li J, Wang J, Guo B (2007) Increased expression of CCR5 in experimental autoimmune myocarditis and reduced severity induced by anti-CCR5 monoclonal antibody. Journal of Molecular and Cellular Cardiology, 42, 781 791.
63. Murphy PM, Baggiolini M, Charo IF et al. (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews, 52, 145 176.
64. Suresh P, Wanchu A (2006) Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics. Journal of Postgraduate Medicine, 52, 210 217.
65. Hammer SM (2002) Increasing choices for HIV therapy. New England Journal of Medicine, 346, 2022 2023.